Beta Bionics Files 8-K: Equity Sales & Bylaw Changes

Ticker: BBNX · Form: 8-K · Filed: Jan 31, 2025 · CIK: 1674632

Beta Bionics, Inc. 8-K Filing Summary
FieldDetail
CompanyBeta Bionics, Inc. (BBNX)
Form Type8-K
Filed DateJan 31, 2025
Risk Levelmedium
Pages4
Reading Time4 min
Key Dollar Amounts$0.0001, $17.00, $229.1 m
Sentimentneutral

Sentiment: neutral

Topics: unregistered-securities, corporate-governance, filing-update

TL;DR

Beta Bionics sold unregistered equity and amended bylaws on Jan 31, 2025.

AI Summary

Beta Bionics, Inc. filed an 8-K on January 31, 2025, reporting unregistered sales of equity securities and amendments to its articles of incorporation or bylaws. The filing also includes other events and financial statements/exhibits, with the company's principal executive offices located at 11 Hughes, Irvine, California.

Why It Matters

This filing indicates Beta Bionics has engaged in unregistered equity sales and made changes to its corporate governance documents, which could impact its capital structure and operational framework.

Risk Assessment

Risk Level: medium — Unregistered equity sales can sometimes signal financial distress or dilution, while changes to bylaws can alter corporate control and operations.

Key Numbers

  • 001-42491 — SEC File Number (Identifies the company's filing history with the SEC.)
  • 47-5386878 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

  • Beta Bionics, Inc. (company) — Registrant
  • January 31, 2025 (date) — Date of Report
  • 11 Hughes, Irvine, California 92618 (location) — Principal Executive Offices

FAQ

What type of equity securities were sold in the unregistered offering?

The filing does not specify the type of equity securities sold in the unregistered offering.

What were the specific amendments made to the articles of incorporation or bylaws?

The filing does not detail the specific amendments made to the articles of incorporation or bylaws.

Were there any material changes reported under 'Other Events'?

The filing lists 'Other Events' as an item information but does not provide specific details within the provided text.

What is the significance of the 'Conformed Period of Report' being January 31, 2025?

This indicates that the information reported in the 8-K filing pertains to events and financial data up to and including January 31, 2025.

What is Beta Bionics, Inc.'s primary business activity?

Beta Bionics, Inc. is classified under 'SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]'.

Filing Stats: 1,064 words · 4 min read · ~4 pages · Grade level 11.3 · Accepted 2025-01-31 17:10:12

Key Financial Figures

  • $0.0001 — ange on which registered Common Stock, $0.0001 par value per share BBNX Nasdaq Glo
  • $17.00 — to the IPO (as defined below) price of $17.00 per share, through a private placement
  • $229.1 m — shares, and the Private Placement were $229.1 million, before deducting underwriting di

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Beta Bionics, Inc. By: /s/ Sean Saint Sean Saint President and Chief Executive Officer Dated: January 31, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.